NGNE - Neurogene Inc.

QQQ $ 611.77 $ -10.06 (-1.61 %)

DIA $ 469.41 $ -2.63 (-0.56 %)

SPY $ 670.48 $ -6.00 (-0.89 %)

TLT $ 89.76 $ 0.19 (0.22 %)

GLD $ 366.16 $ -1.03 (-0.28 %)

Previous Close

$ 27.72

Open

$ 27.07

Bid

$ 26.51 x 1

Ask

$ 26.62 x 195

Day's Range

$ 25.00 - $ 27.36

52 Week Range

$ 6.88 - $ 74.49

Volume

416,419

Average Volume

Market Cap

583.66M

Beta (5Y Monthly)

$ 3.89

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-09-2025	03-31-2025	10-Q
3	03-24-2025	12-31-2024	10-K
4	11-18-2024	09-30-2024	10-Q
5	08-09-2024	06-30-2024	10-Q
6	05-10-2024	03-31-2024	10-Q
7	03-18-2024	12-31-2023	10-K
8	11-14-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	03-20-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	03-01-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-12-2021	03-31-2021	10-Q
19	03-25-2021	12-31-2020	10-K
20	11-09-2020	09-30-2020	10-Q
21	08-12-2020	06-30-2020	10-Q
22	05-06-2020	03-31-2020	10-Q
23	03-12-2020	12-31-2019	10-K
24	11-13-2019	09-30-2019	10-Q
25	08-01-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-07-2019	12-31-2018	10-K
28	11-07-2018	09-30-2018	10-Q
29	08-08-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	03-12-2018	12-31-2017	10-K
32	11-08-2017	09-30-2017	10-Q
33	08-08-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	03-09-2017	12-31-2016	10-K
36	11-09-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-10-2016	03-31-2016	10-Q
39	03-14-2016	12-31-2015	10-K
40	11-10-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Neurogene Doses First Participant In Its E...
11/06/2025 12:35:11

fdas-rigid-approach-adds-uncertainty-to-uniqures-accelerated-pathway-for-huntingtons-gene-therapy

FDA's Rigid Approach Adds Uncertainty To u...
11/04/2025 19:25:08

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval ...

apple-to-rally-around-20-here-are-10-top-analyst-forecasts-for-friday

Apple To Rally Around 20%? Here Are 10 Top...
10/31/2025 11:53:10

HC Wainwright & Co. Maintains Buy on Neuro...
10/31/2025 10:58:48

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target ...

12 Health Care Stocks Moving In Thursday's...
10/09/2025 17:06:06

HC Wainwright & Co. Reiterates Buy on Neur...
10/09/2025 14:32:50

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $45 price tar...

Neurogene Completes Discussions With FDA O...
10/09/2025 11:08:12

Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollmentNew preclinical data at ESGCT ...

4-biotech-stocks-seeing-explosive-momentum-gains

4 Biotech Stocks Seeing Explosive Momentum...
10/07/2025 15:19:18

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...

fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA Outlines Process To Speed Up Rare Dise...
09/04/2025 18:50:03

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

Neurogene Q2 EPS $(1.05) Beats $(1.16) Est...
08/11/2025 20:22:34

vinay-prasads-comeback-to-fda-sparks-debate-over-regulatory-direction

Vinay Prasad's Comeback To FDA Sparks Deba...
08/11/2025 12:45:28

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vac...

whats-going-on-with-sarepta-capricor-and-other-gene-therapy-stocks-on-wednesday

What's Going On With Sarepta, Capricor And...
07/30/2025 15:07:26

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controve...

12 Health Care Stocks Moving In Friday's A...
07/11/2025 21:06:01

12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 17:05:56

Neurogene Announces Written Agreement From...
06/30/2025 20:07:02

Craig-Hallum Initiates Coverage On Neuroge...
06/17/2025 14:01:40

Craig-Hallum analyst Albert Lowe initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and announces Price Target ...

BMO Capital Maintains Outperform on Neurog...
06/12/2025 15:00:55

BMO Capital analyst Evan David Seigerman maintains Neurogene (NASDAQ:NGNE) with a Outperform and raises the price target fro...

BMO Capital Maintains Outperform on Neurog...
05/20/2025 13:03:48

BMO Capital analyst Keith Tapper maintains Neurogene (NASDAQ:NGNE) with a Outperform and raises the price target from $16 to...

this-foot-locker-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-friday

This Foot Locker Analyst Is No Longer Bull...
05/16/2025 15:29:17

Baird Downgrades Neurogene to Neutral, Low...
05/16/2025 14:19:48

Baird analyst Joel Beatty downgrades Neurogene (NASDAQ:NGNE) from Outperform to Neutral and lowers the price target from $38...